Methylated tumor-specific DNA as a plasma biomarker in patients with glioma
- PMID: 16466990
- DOI: 10.1080/07357900500449546
Methylated tumor-specific DNA as a plasma biomarker in patients with glioma
Abstract
Objective: Patients with systemic malignancies have substantial quantities of tumor-specific DNA in their plasma which may serve as a potential biomarker for tumor burden. This approach has not been studied in gliomas.
Methods: Methylation specific polymerase chain reaction (MSP) was used to determine the methylation status the promoters for p16/(INK4a), MGMT, p73, and RARbeta within glioma tissue and plasma. Blood was collected prior to craniotomy in 10 patients with glioma. DNA was extracted from tumor and plasma samples and assayed with MSP. Total plasma DNA also was quantified. Tumor-specific plasma DNA was defined as identification of the same methylated promoter (MP) in both tumor and plasma.
Results: Total plasma DNA concentration was markedly elevated (mean 6,503 ng/ml, SEM 1,400 ng/ml). Glioma tissue contained methylation of at least one promoter in 9 out of 10 (90 percent) of patients studied. Of these patients, 6 out of 9 (67 percent) demonstrated methylation of at least one of the same promoters in plasma. Five of these had one MP identified in the plasma and one had 2 MP. Overall, glioma-specific plasma DNA was present in plasma of 6 out of 10 (60 percent) of patients. Each MP DNA marker found in the plasma also was present in the intracranial tumor.
Conclusions: Patients with high grade gliomas have large amounts of DNA in the plasma. Of these primary brain tumors, 90 percent contained methylated gene promoters, and in over 60 percent of these patients the same methylated promoters present in the tumor also were found in the plasma. This represents the first step to developing a quantitative plasma biomarker that could be used to monitor glioma status.
Similar articles
-
p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas.Neurosurgery. 2009 Mar;64(3):455-61; discussion 461-2. doi: 10.1227/01.NEU.0000340683.19920.E3. Neurosurgery. 2009. PMID: 19240607
-
Aberrant promoter hypermethylation in serum DNA from patients with silicosis.Carcinogenesis. 2008 Sep;29(9):1845-9. doi: 10.1093/carcin/bgn169. Epub 2008 Jul 16. Carcinogenesis. 2008. PMID: 18632757
-
Concurrent methylation of multiple genes in childhood ALL: Correlation with phenotype and molecular subgroup.Leukemia. 2003 Sep;17(9):1845-50. doi: 10.1038/sj.leu.2403060. Leukemia. 2003. PMID: 12970785
-
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.Neurosurgery. 2010 Dec;67(6):1681-91. doi: 10.1227/NEU.0b013e3181f743f5. Neurosurgery. 2010. PMID: 21107199 Review.
-
O6 -methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: a review of current status.Neurol India. 2011 Mar-Apr;59(2):229-35. doi: 10.4103/0028-3886.79128. Neurol India. 2011. PMID: 21483124 Review.
Cited by
-
Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.J Neurooncol. 2015 Jul;123(3):373-83. doi: 10.1007/s11060-015-1730-4. Epub 2015 Feb 21. J Neurooncol. 2015. PMID: 25697584 Review.
-
Molecular epigenetics and genetics in neuro-oncology.Neurotherapeutics. 2009 Jul;6(3):436-46. doi: 10.1016/j.nurt.2009.04.002. Neurotherapeutics. 2009. PMID: 19560734 Free PMC article. Review.
-
Dexamethasone in Glioblastoma Multiforme Therapy: Mechanisms and Controversies.Front Mol Neurosci. 2019 Mar 29;12:65. doi: 10.3389/fnmol.2019.00065. eCollection 2019. Front Mol Neurosci. 2019. PMID: 30983966 Free PMC article. Review.
-
Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma.Cancer Res Treat. 2022 Apr;54(2):597-612. doi: 10.4143/crt.2021.752. Epub 2021 Jul 23. Cancer Res Treat. 2022. PMID: 34325497 Free PMC article.
-
Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.BMC Cancer. 2019 Mar 1;19(1):192. doi: 10.1186/s12885-019-5394-x. BMC Cancer. 2019. PMID: 30823914 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials